Hepatic enhancement during the hepatobiliary phase after gadoxetate disodium administration in patients with chronic liver disease: The role of laboratory factors

Victoria Chernyak, Jane Kim, Alla Rozenblit, Fernanda Mazzoriol, Zina Ricci

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Purpose: To identify factors influencing hepatobiliary phase (HBP) hepatic enhancement on gadoxetate disodium-enhanced MRI in patients with chronic liver disease (CLD). Materials and Methods: We retrospectively reviewed abdominal gadoxetate disodium-enhanced MRIs and medical records of patients with (n = 97) and without (n = 48) CLD. CLD subgroups were formed based on normal/abnormal components of liver function tests (LFTs). Hepatic enhancement coefficients (HEKs) were calculated on MRI, and compared with LFTs and Model for End-stage Liver Disease (MELD) scores. Results: The mean HEK was significantly lower (P < 0.0008) in the CLD than control group. The mean HEK was similar to controls in the subgroup with all normal LFTs (P = 0.09) and subgroup with normal direct bilirubin (DB) (p = 0.09), while it was significantly reduced (P < 0.0001) in the subgroup with elevated DB. For all other LFT components, regardless of normal or abnormal values, there was a significant reduction in the mean HEKs versus controls (all P values <0.01). There was a highly negative correlation between the mean HEKs in CLD subgroups and number of abnormal LFTs (r = -0.93) and MELD scores (r = -0.89). Conclusion: HBP hepatic enhancement in CLD patients is similar to those with no CLD as long as direct bilirubin remains normal. Higher MELD scores and higher number of abnormal LFT components are associated with reduced hepatic enhancement.

Original languageEnglish (US)
Pages (from-to)301-309
Number of pages9
JournalJournal of Magnetic Resonance Imaging
Volume34
Issue number2
DOIs
StatePublished - Aug 2011

Fingerprint

Liver Function Tests
Liver Diseases
Chronic Disease
Liver
End Stage Liver Disease
Bilirubin
gadolinium ethoxybenzyl DTPA
Medical Records
Control Groups

Keywords

  • cirrhosis
  • gadoxetate disodium
  • liver imaging
  • parenchymal liver disease

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Hepatic enhancement during the hepatobiliary phase after gadoxetate disodium administration in patients with chronic liver disease : The role of laboratory factors. / Chernyak, Victoria; Kim, Jane; Rozenblit, Alla; Mazzoriol, Fernanda; Ricci, Zina.

In: Journal of Magnetic Resonance Imaging, Vol. 34, No. 2, 08.2011, p. 301-309.

Research output: Contribution to journalArticle

@article{b696f8d9bd674e168830fd63750ece0b,
title = "Hepatic enhancement during the hepatobiliary phase after gadoxetate disodium administration in patients with chronic liver disease: The role of laboratory factors",
abstract = "Purpose: To identify factors influencing hepatobiliary phase (HBP) hepatic enhancement on gadoxetate disodium-enhanced MRI in patients with chronic liver disease (CLD). Materials and Methods: We retrospectively reviewed abdominal gadoxetate disodium-enhanced MRIs and medical records of patients with (n = 97) and without (n = 48) CLD. CLD subgroups were formed based on normal/abnormal components of liver function tests (LFTs). Hepatic enhancement coefficients (HEKs) were calculated on MRI, and compared with LFTs and Model for End-stage Liver Disease (MELD) scores. Results: The mean HEK was significantly lower (P < 0.0008) in the CLD than control group. The mean HEK was similar to controls in the subgroup with all normal LFTs (P = 0.09) and subgroup with normal direct bilirubin (DB) (p = 0.09), while it was significantly reduced (P < 0.0001) in the subgroup with elevated DB. For all other LFT components, regardless of normal or abnormal values, there was a significant reduction in the mean HEKs versus controls (all P values <0.01). There was a highly negative correlation between the mean HEKs in CLD subgroups and number of abnormal LFTs (r = -0.93) and MELD scores (r = -0.89). Conclusion: HBP hepatic enhancement in CLD patients is similar to those with no CLD as long as direct bilirubin remains normal. Higher MELD scores and higher number of abnormal LFT components are associated with reduced hepatic enhancement.",
keywords = "cirrhosis, gadoxetate disodium, liver imaging, parenchymal liver disease",
author = "Victoria Chernyak and Jane Kim and Alla Rozenblit and Fernanda Mazzoriol and Zina Ricci",
year = "2011",
month = "8",
doi = "10.1002/jmri.22635",
language = "English (US)",
volume = "34",
pages = "301--309",
journal = "Journal of Magnetic Resonance Imaging",
issn = "1053-1807",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Hepatic enhancement during the hepatobiliary phase after gadoxetate disodium administration in patients with chronic liver disease

T2 - The role of laboratory factors

AU - Chernyak, Victoria

AU - Kim, Jane

AU - Rozenblit, Alla

AU - Mazzoriol, Fernanda

AU - Ricci, Zina

PY - 2011/8

Y1 - 2011/8

N2 - Purpose: To identify factors influencing hepatobiliary phase (HBP) hepatic enhancement on gadoxetate disodium-enhanced MRI in patients with chronic liver disease (CLD). Materials and Methods: We retrospectively reviewed abdominal gadoxetate disodium-enhanced MRIs and medical records of patients with (n = 97) and without (n = 48) CLD. CLD subgroups were formed based on normal/abnormal components of liver function tests (LFTs). Hepatic enhancement coefficients (HEKs) were calculated on MRI, and compared with LFTs and Model for End-stage Liver Disease (MELD) scores. Results: The mean HEK was significantly lower (P < 0.0008) in the CLD than control group. The mean HEK was similar to controls in the subgroup with all normal LFTs (P = 0.09) and subgroup with normal direct bilirubin (DB) (p = 0.09), while it was significantly reduced (P < 0.0001) in the subgroup with elevated DB. For all other LFT components, regardless of normal or abnormal values, there was a significant reduction in the mean HEKs versus controls (all P values <0.01). There was a highly negative correlation between the mean HEKs in CLD subgroups and number of abnormal LFTs (r = -0.93) and MELD scores (r = -0.89). Conclusion: HBP hepatic enhancement in CLD patients is similar to those with no CLD as long as direct bilirubin remains normal. Higher MELD scores and higher number of abnormal LFT components are associated with reduced hepatic enhancement.

AB - Purpose: To identify factors influencing hepatobiliary phase (HBP) hepatic enhancement on gadoxetate disodium-enhanced MRI in patients with chronic liver disease (CLD). Materials and Methods: We retrospectively reviewed abdominal gadoxetate disodium-enhanced MRIs and medical records of patients with (n = 97) and without (n = 48) CLD. CLD subgroups were formed based on normal/abnormal components of liver function tests (LFTs). Hepatic enhancement coefficients (HEKs) were calculated on MRI, and compared with LFTs and Model for End-stage Liver Disease (MELD) scores. Results: The mean HEK was significantly lower (P < 0.0008) in the CLD than control group. The mean HEK was similar to controls in the subgroup with all normal LFTs (P = 0.09) and subgroup with normal direct bilirubin (DB) (p = 0.09), while it was significantly reduced (P < 0.0001) in the subgroup with elevated DB. For all other LFT components, regardless of normal or abnormal values, there was a significant reduction in the mean HEKs versus controls (all P values <0.01). There was a highly negative correlation between the mean HEKs in CLD subgroups and number of abnormal LFTs (r = -0.93) and MELD scores (r = -0.89). Conclusion: HBP hepatic enhancement in CLD patients is similar to those with no CLD as long as direct bilirubin remains normal. Higher MELD scores and higher number of abnormal LFT components are associated with reduced hepatic enhancement.

KW - cirrhosis

KW - gadoxetate disodium

KW - liver imaging

KW - parenchymal liver disease

UR - http://www.scopus.com/inward/record.url?scp=79960577313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960577313&partnerID=8YFLogxK

U2 - 10.1002/jmri.22635

DO - 10.1002/jmri.22635

M3 - Article

C2 - 21608069

AN - SCOPUS:79960577313

VL - 34

SP - 301

EP - 309

JO - Journal of Magnetic Resonance Imaging

JF - Journal of Magnetic Resonance Imaging

SN - 1053-1807

IS - 2

ER -